ArticleJournal of translational medicine2025
Exosomes derived from hypoxia-preconditioned M2 macrophages alleviate degeneration in knee osteoarthritis through the miR‑124‑3p/STAT3 axis.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Immune dysregulation in osteoarthritis: Mechanisms, biomarkers, and therapeutic opportunities.Journal of translational autoimmunity · 2026Review
- Small extracellular vesicles in osteoarthritis: A double‑edged sword regulating inflammation and cartilage homeostasis (Review).International journal of molecular medicine · 2026Review
- DNA methylation-mediated silencing of MALAT1 promotes dexamethasone-induced growth plate chondrocyte ferroptosis via miR-124-3p/LPCAT3.Journal of bioenergetics and biomembranes · 2026Article
- Single-cell and spatial transcriptomics analysis of osteoarthritis: pathway regulation, cell interaction networks, and therapeutic translation.Journal of translational medicine · 2026Review
- Research progress on the effects of macrophage‑derived exosomes on muscle factors IGF‑1 and FGF‑2 mediating musculoskeletal crosstalk molecular signaling pathway on bone metabolism (Review).International journal of molecular medicine · 2026Review
- Unlocking the potential of engineered exosomes for knee osteoarthritis therapy.Frontiers in immunology · 2026Review
- Research progress and prospects of exosomes from diverse cellular sources in the treatment of knee osteoarthritis: a narrative review.Frontiers in surgery · 2026Review
- Exosome-derived ncRNAs and proteins: inflammation regulatory mechanisms and biomarker potential in spinal cord injury.Frontiers in molecular biosciences · 2026Review
- Key Role of STAT3 in Osteoarthritis: From Pathogenic Mechanisms to Targeted Therapy.International journal of nanomedicine · 2025Review
- MicroRNAs as Key Regulators of Degeneration and Inflammation in Osteoarthritis: A Narrative Review.Saudi journal of medicine & medical sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundM2 macrophages-derived exosomes (M2φ-Exos) have been demonstrated to effectively alleviate osteoarthritis (OA) in animal models. Hypoxic preconditioning is commonly used to enhance the biological effects of stem cell-derived exosomes, but its impact on M2φ-Exos remains unclear. This study aims to investigate whether hypoxic preconditioning could enhance the biological effects of M2φ-Exos in OA treatment and to explore the underlying molecular mechanisms, with the goal of providing new insights for the development of safe and effective OA therapeutic strategies.
methodsExosomes were extracted from the supernatants of M2 macrophages cultured under normoxic or hypoxic conditions using low-temperature differential ultracentrifugation and were designated as Nor-Exos and Hypo-Exos. The exosomes were characterized by transmission electron microscopy, nanoparticle tracking analysis, and Western blotting. To evaluate the impact of hypoxic preconditioning on the biological effects of M2φ-Exos, the therapeutic effects of Nor-Exos and Hypo-Exos were assessed in an IL-1β-induced chondrocyte inflammation model and a rat knee OA model established by surgical intervention. Exosomal miRNAs with differential expression between Nor-Exos and Hypo-Exos were identified through exosomal miRNA sequencing. The miRNA with the highest upregulation in Hypo-Exos was selected for further functional validation. To investigate the role of this miRNA, miRNA inhibitors were used to knock down its expression in Hypo-Exos, and the subsequent impact of this change on Hypo-Exos activity was evaluated. Bioinformatic tools and dual-luciferase reporter assays were used to predict and verify the downstream target genes of the miRNA. Target gene expression was knocked down using small interfering RNA, and the effect of downregulating target gene expression on the inhibitory effect of low miRNA expression on Hypo-Exos was observed at the cellular level.
resultsCompared to Nor-Exos, Hypo-Exos exhibited more effective therapeutic effects in both inflammatory chondrocytes and OA rats. miR-124-3p was identified as the most upregulated miRNA in Hypo-Exos, and the suppression of miR-124-3p expression significantly inhibited the biological effects of Hypo-Exos. STAT3 was determined to be a downstream target gene of miR-124-3p. Further cellular experiments revealed that downregulation of STAT3 expression in chondrocytes successfully alleviated the inhibitory effect of low miR-124-3p expression on the biological effects of Hypo-Exos.
conclusionsHypoxic preconditioning enhances the biological effects of M2φ-Exos in the treatment of OA. The underlying molecular mechanism is associated with increased delivery of miR-124-3p to chondrocytes, which subsequently inhibits the post-transcriptional expression of STAT3. This provides a promising therapeutic strategy for the clinical intervention of OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.